ClinicalTrials.gg
RecruitingNCT04626050Updated Jun 22, 2026

General Psychological Distress, PTSD, and Co-Morbidities in Healthcare Workers Consequent to Occupational Trauma

An interventional study of Medical Music and Narrative Writing in Post-traumatic Stress Disorder and Moral Injury, sponsored by Weill Medical College of Cornell University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Stress Disorders, Post-Traumatic by Weill Medical College of Cornell University — 4 open to participants now, 4 under way, none of them phase 3. Stress Disorders, Post-Traumatic · Weill Medical College of Cornell University.

Planned enrollment
3rd of 12
120 · median 23
Started
2022
the only one that year
No phase
7 of 14
3 open now
Registered
12th of 14
by date

Among the 14 studies in Stress Disorders, Post-Traumatic by Weill Medical College of Cornell University, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2022, is one of 7 with no phase, and was the 12th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

4 of the 14 studies in Stress Disorders, Post-Traumatic by Weill Medical College of Cornell University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Stress Disorders, Post-Traumatic by Weill Medical College of Cornell University, or all of them as a file.
02

Study summary

It is expected that large numbers of healthcare workers experience a broad range of psychological reactions and symptoms including anxiety, depression, moral distress, and trauma symptoms that will cause both significant suffering as well as occupational and social impairment. The purpose of this study is to find interventions which are helpful in treating psychological distress in healthcare workers adversely affected by occupational-related trauma.

There are two phases of the study. All participants will take part in Phase I, which consists of 4 sessions over a two-week period of either a narrative writing intervention or a medical music intervention. Participants will be randomly assigned to the narrative writing intervention or medical music intervention.

After Phase I, participants will be re-assessed. Healthcare workers who meet criteria for PTSD will be given the option to participate in Phase II of the study, in which they will be offered a choice between one of two evidence-based treatments for PTSD: Interpersonal Therapy (IPT) or Exposure Therapy (ET). Both treatments are comprised of ten 75-minute sessions scheduled twice weekly. Participants will be allowed to choose a preferred treatment in Phase II. After Phase II participants will complete a final assessment concluding the study. All interventions will be offered using distance technology.

03

Conditions studied

  • Post-traumatic Stress Disorder
  • Moral Injury

Keywords

  • PTSD
  • Moral Injury
  • Psychological Distress
  • Healthcare Workers
  • Occupational Trauma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any healthcare worker providing medical care or support who has experienced occupational-related trauma
  • English-speaking
  • Age >18
  • Medically stable
  • Able to provide and function at an intellectual level sufficient to allow accurate completion of all assessment instruments
  • If on psychotropic medication stable for prior 60 days

For phase II additional inclusion criteria:

- Current diagnosis of PTSD

Exclusion criteria

Exclusion Criteria:

  • Current significant unstable medical illness precluding regular session attendance or assessment completion
  • Participants who in the investigator's judgment pose a current homicidal, suicidal, or other risk
  • Lifetime or current diagnosis of schizophrenia or other psychotic disorder
  • Participation in a clinical trial or concurrent evidence-based treatment for psychiatric conditions or PTSD during the previous 3 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Medical Music (Phase I)

    Participants will complete four medical music sessions that are 20 minutes in length each.

    Behavioral: Medical Music

  • Experimental
    Narrative Writing (Phase I)

    Participants will complete four narrative writing sessions that are 20 minutes in length each.

    Behavioral: Narrative Writing

  • Active comparator
    Interpersonal Psychotherapy (Phase II)

    IPT is comprised of ten 75-minute sessions scheduled twice weekly.

    Behavioral: Interpersonal Psychotherapy

  • Active comparator
    Prolonged Exposure Therapy (Phase II)

    ET is comprised of ten 75-minute sessions scheduled twice weekly.

    Behavioral: Prolonged Exposure Therapy

Interventions

  • BehavioralMedical Music

    Participants randomized to this condition will complete 4 medical music sessions over the course of 2 weeks

  • BehavioralNarrative Writing

    Participants randomized to this condition will complete 4 narrative writing sessions over the course of 2 weeks

  • BehavioralProlonged Exposure Therapy

    Psychotherapy including imaginal exposure for PTSD

  • BehavioralInterpersonal Psychotherapy

    Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning

06

What researchers measure

Primary outcomes

  1. Feasibility Indicator: Recruitment (Phase I)

    Feasibility assessment will include recruitment defined as number of individuals interested in the intervention.

    Time frame: Baseline

  2. Feasibility Indicator: Recruitment (Phase II)

    Feasibility assessment will include: recruitment defined as number of individuals interested in the intervention.

    Time frame: Post-Phase I Assessment at week 2

  3. Feasibility Indicator: Enrollment (Phase I)

    Feasibility assessment will include enrollment defined as number of participants signing the informed consent form.

    Time frame: Baseline

  4. Feasibility Indicator: Enrollment (Phase II)

    Feasibility assessment will include enrollment defined as number of individuals beginning phase II.

    Time frame: Post-Phase I Assessment at approximately week 2

  5. Feasibility Indicator: Retention (Phase I)

    Feasibility assessment will include retention defined as the number of participants completing the full course of Phase I interventions.

    Time frame: Post-Phase I Assessment at approximately week 2

  6. Feasibility Indicator: Retention (Phase II)

    Feasibility assessment will include retention defined as the number of participants completing the full course of Phase II interventions.

    Time frame: Post-Phase II Assessment at approximately week 7

  7. Acceptability Indicator: Satisfaction (Phase I)

    Acceptability and treatment satisfaction will be rated with a Likert scale.

    Time frame: Post-Phase I Assessment at approximately week 2

  8. Acceptability Indicator: Satisfaction (Phase II)

    Acceptability and treatment satisfaction will be rated with a Likert scale.

    Time frame: Post-Phase II Assessment at approximately week 7

  9. Preliminary Efficacy as Measured by Change in Clinician-Administered PTSD Scale Score (Phase I)

    Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Score. Total Scores range from 0-80. Higher scores indicate greater symptom severity.

    Time frame: Start of Phase I to approximately 2 weeks

  10. Preliminary Efficacy as Measured by Change in Clinician-Administered PTSD Scale Score (Phase II)

    Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Score. Total Scores range from 0-80. Higher scores indicate greater symptom severity.

    Time frame: Start of Phase II to approximately 5 weeks

Secondary outcomes

  1. Change in Anxiety Symptoms measured by the Generalized Anxiety Disorder 7-Item Scale (Phase I)

    Scored between 0-21: Cut offs: 0-4 = None 5-9 = Mild anxiety 10-14 = Moderate anxiety 15-21 = Severe anxiety Higher scores indicate greater symptom severity.

    Time frame: Start of Phase I to approximately 2 weeks

  2. Change in Anxiety Symptoms measured by the Generalized Anxiety Disorder 7-Item Scale (Phase II)

    Scored between 0-21: Cut offs: 0-4 = None 5-9 = Mild anxiety 10-14 = Moderate anxiety 15-21 = Severe anxiety Higher scores indicate greater symptom severity.

    Time frame: Start of Phase II to approximately 5 weeks

  3. Change in Depressive Symptoms measured by the Quick Inventory of Depressive Symptomology (Phase I)

    16-item self-report measure. Scored between 0-3. Higher scores indicate greater symptom severity

    Time frame: Start of Phase I to approximately 2 weeks

  4. Change in Depressive Symptoms measured by the Quick Inventory of Depressive Symptomology (Phase II)

    16-item self-report measure. Scored between 0-3. Higher scores indicate greater symptom severity.

    Time frame: Start of Phase II to approximately 5 weeks

  5. Change in score on the Pittsburgh Sleep Quality Index (PSQI) (Phase I)

    24 item self-report measure. 19 questions are evaluated. Each item in the scale is rated between 0 (no distress) and 3 (serious distress). The total PSQI score ranges from 0-21. Sleep quality of the patients with a total score of 5 and below is considered "good". A score of greater than 5 refers to poor sleep quality.

    Time frame: Start of Phase I to approximately 2 weeks

  6. Change in score on the Pittsburgh Sleep Quality Index (PSQI) (Phase II)

    24 item self-report measure. 19 questions are evaluated. Each item in the scale is rated between 0 (no distress) and 3 (serious distress). The total PSQI score ranges from 0-21. Sleep quality of the patients with a total score of 5 and below is considered "good". A score of greater than 5 refers to poor sleep quality.

    Time frame: Start of Phase II to approximately 5 weeks

  7. Change in score on the Moral Injury Symptom Scale: Healthcare Professionals Version (Phase I)

    11 item self-report measure measuring one's experiences as a healthcare professional and how they are feeling currently. Scored between 1-10. Higher scores indicate greater moral distress.

    Time frame: Start of Phase I to approximately 2 weeks

  8. Change in score on the Moral Injury Symptom Scale: Healthcare Professionals Version (Phase II)

    11 item self-report measuring one's experiences as a healthcare professional and how they are feeling currently. Scored between 1-10. Higher scores indicate greater moral distress.

    Time frame: Start of Phase II to approximately 5 weeks

  9. Change in score on the Modified Moral Injury Events Scale (Phase I)

    11 item self-report measure that measures moral injury. Statements related to distress or feelings of betrayal related to potentially morally injurious events are rated on a 6 point scale ranging from 1 (strongly agree) to 6 (strongly disagree). Score range is 11-66, with higher scores reflecting greater moral injury.

    Time frame: Start of Phase I to approximately 2 weeks

  10. Change in score on the Modified Moral Injury Events Scale (Phase II)

    11 item self-report measure that measures moral injury. Statements related to distress or feelings of betrayal related to potentially morally injurious events are rated on a 6 point scale ranging from 1 (strongly agree) to 6 (strongly disagree). Score range is 11-66, with higher scores reflecting greater moral injury.

    Time frame: Start of Phase II to approximately 5 weeks

  11. Change in score on the PTSD Checklist for DSM-5 (PCL-5) (Phase I)

    The well-validated PCL-5 will assess self-reported PTSD symptom severity. Scores range from 0-80. Higher scores indicate greater symptom severity.

    Time frame: Start of Phase I to approximately 2 weeks

  12. Change in score on the PTSD Checklist for DSM-5 (PCL-5) (Phase II)

    The well-validated PCL-5 will assess self-reported PTSD symptom severity. Scores range from 0-80. Higher scores indicate greater symptom severity.

    Time frame: Start of Phase II to approximately 5 weeks

  13. Change in score on the Sheehan Disability Scale (SDS) (Phase I)

    10 point visual analog scale to rate the extent to which work/school, social life and home life or family responsibilities are impaired by his or her symptoms. The 3 items can be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).

    Time frame: Start of Phase I to approximately 2 weeks

  14. Change in score on the Sheehan Disability Scale (SDS) (Phase II)

    10 point visual analog scale to rate the extent to which work/school, social life and home life or family responsibilities are impaired by his or her symptoms. The 3 items can be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).

    Time frame: Start of Phase II to approximately 5 weeks

  15. Change in score on the World Health Organization Quality of Life Scale - Brief (Phase I)

    The minimum score is 0 and the maximum score is 100. High score shows better result.

    Time frame: Start of Phase I to approximately 2 weeks

  16. Change in score on the World Health Organization Quality of Life Scale - Brief (Phase II)

    The minimum score is 0 and the maximum score is 100. High score shows better result.

    Time frame: Start of Phase II to approximately 5 weeks

  17. Change in score on the Work and Social Adjustment Scale (WSAS) (Phase I)

    5 items measuring one's social functioning on items covering ability to work, home management, social leisure activities, private leisure activities, and close relationships. Each item is scored between 0-8. Lower scores are better.

    Time frame: Start of Phase I to approximately 2 weeks

  18. Change in score on the Work and Social Adjustment Scale (WSAS) (Phase II)

    5 items measuring one's social functioning on items covering ability to work, home management, social leisure activities, private leisure activities, and close relationships. Each item is scored between 0-8. Lower scores are better.

    Time frame: Start of Phase II to approximately 5 weeks

  19. Change in Score on the Occupational Stress Inventory Revised (OSI-R) (Phase I)

    The scale is comprised of 140 items total. The measure is comprised of 14 different scales and respondents indicate on a 5-point scale the frequency of a stress-related event.

    Time frame: Start of Phase I to approximately 2 weeks

  20. Change in Score on the Occupational Stress Inventory Revised (OSI-R) (Phase II)

    The scale is comprised of 140 items total. The measure is comprised of 14 different scales and respondents indicate on a 5-point scale the frequency of a stress-related event.

    Time frame: Start of Phase II to approximately 5 weeks

  21. Change in Score on the Multidimensional Scale of Perceived Social Support (MSPSS) (Phase I)

    12-item scale with a seven-point scale (from 1=strongly disagree to 7=strongly agree), resulting in a total score in the range of 12-84. Higher scores indicate higher perceived social support by Friends and Family/Significant Others.

    Time frame: Start of Phase I to approximately 2 weeks

  22. Change in Score on the Multidimensional Scale of Perceived Social Support (MSPSS) (Phase II)

    12-item scale with a seven-point scale (from 1=strongly disagree to 7=strongly agree), resulting in a total score in the range of 12-84. Higher scores indicate higher perceived social support by Friends and Family/Significant Others.

    Time frame: Start of Phase II to approximately 5 weeks

  23. Change in score on the Posttraumatic Cognitions Inventory (Phase I)

    33-item self-report measure is designed to assess the degree to which a participant agrees with thoughts and beliefs that have been found to be common for individuals who suffer from PTSD. The measure is rated between 1 (Totally disagree) to 7 (Totally agree). The score range is 33-231. Higher scores indicate greater symptom severity.

    Time frame: Start of Phase I to approximately 2 weeks

  24. Change in score on the Posttraumatic Cognitions Inventory (Phase II)

    33-item self-report measure is designed to assess the degree to which a participant agrees with thoughts and beliefs that have been found to be common for individuals who suffer from PTSD. The measure is rated between 1 (Totally disagree) to 7 (Totally agree). The score range is 33-231. Higher scores indicate greater symptom severity.

    Time frame: Start of Phase II to approximately 5 weeks

  25. Change in score on the Difficulties in Emotion Regulation Scale-18 (DERS-18) (Phase I)

    The Difficulties in Emotion Regulation Scale-18 (DERS) is a 18-item self-report measure of six facets of emotion regulation. Items are rated on a scale of 1 ("almost never \[0-10%\]") to 5 ("almost always \[91-100%\]"). Higher scores indicate more difficulty in emotion regulation.

    Time frame: Start of Phase I to approximately 2 weeks

  26. Change in score on the Difficulties in Emotion Regulation Scale-18 (Phase II)

    The Difficulties in Emotion Regulation Scale-18 (DERS-18) is a 18-item self-report measure of six facets of emotion regulation. Items are rated on a scale of 1 ("almost never \[0-10%\]") to 5 ("almost always \[91-100%\]"). Higher scores indicate more difficulty in emotion regulation.

    Time frame: Start of Phase II to approximately 5 weeks

  27. Change in score on the Pittsburgh Insomnia Rating Scale-20 Item Version (PIRS_20)

    The Pittsburgh Insomnia Rating Scale is a 20 item self report measure. Items are rated on a scale from 0-3. Higher scores indicate higher insomnia severity.

    Time frame: Start of Phase I to approximately 2 weeks

  28. Change in score on the Pittsburgh Insomnia Rating Scale-20 Item Version (PIRS_20)

    The Pittsburgh Insomnia Rating Scale is a 20 item self report measure. Items are rated on a scale from 0-3. Higher scores indicate higher insomnia severity.

    Time frame: Start of Phase II to approximately 5 weeks

07

Study locations

1 of 1 sites recruiting
  • Weill Cornell Medicine
    New York, New York 10065, United States
    Recruiting
    • Olivia Baryluk, BS · Contact
    • JoAnn Difede, PhD · Principal investigator
08

References and documents

Publications

  • Wang CC, Difede J. A Two-Phased Telehealth Model to Treat Post-Traumatic Stress Disorder in a Health Care Worker due to the COVID-19 Pandemic: A Case Report. Telemed J E Health. 2024 Feb;30(2):601-606. doi: 10.1089/tmj.2023.0326. Epub 2023 Aug 16. PubMed 37585569 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jan 2028, 72 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 72 months is above that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2020
First posted
Nov 12, 2020
StartActual
Jan 20, 2022
Primary completionEst.
Jan 2028
CompletionEst.
Apr 2028
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04626050
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Jan 20, 2022
Primary completion
Jan 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Jun 22, 2026

Study contacts

Olivia Baryluk, BS
Contact
olb4002@med.cornell.edu
212-821-0783
JoAnn Difede, PhD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion